Latest News

Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial
Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial

April 4th 2025

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

 Oral Semaglutide Lowers Risk of MACE 14% in Adults with T2D, ASCVD and/or CKD: Final Phase 3 SOUL Trial Readout/ image credit American College of Cardiology
Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout

March 31st 2025

CagriSema Achieves Significant Weight Loss in Phase 3 Trial: Daily Dose / image credit: ©New Africa/AdobeStock
CagriSema Achieves Significant Weight Loss in Phase 3 Trial: Daily Dose

March 31st 2025

Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin Plus CGM
Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin with CGM

March 27th 2025

Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Tablet for Obesity / image credit ©Viking Therapeutics
Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet

March 26th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.